Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 | P03372 | 12/20 | 0.84 |
| ▸ | ESR2 | Q92731 | 2/20 | 0.84 |
| ▸ | HSD17B3 | P37058 | 3/20 | 0.67 |
| ▸ | ERAP1 | Q9NZ08 | 2/20 | 0.67 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.67 |
| ▸ | GLA | P06280 | 1/20 | 0.67 |
| ▸ | GAA | P10253 | 1/20 | 0.67 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.67 |
| ▸ | AR | P10275 | 1/20 | 0.62 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.58 |
| ▸ | ACP1 | P24666 | 2/20 | 0.58 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13346053 | 0.92 | ESR1 (0.79) | ESR1ESR2HSD17B3ERAP1KDM4E | |
| SCHEMBL12729873 | 0.92 | ESR1 (1.00) | ESR1ESR2HSD17B3ERAP1KDM4E | |
| SCHEMBL25079563 | 0.89 | ESR1 (0.71) | ESR1ESR2HSD17B3ERAP1KDM4E | |
| SCHEMBL13183969 | 0.87 | ESR1 (1.00) | ESR1ESR2 | |
| SCHEMBL14428675 | 0.85 | ESR1 (0.63) | ESR1ESR2HSD17B3ERAP1KDM4E | |
| SCHEMBL5142252 | 0.84 | CYP19A1 (0.74) | ESR1ESR2HSD17B3ERAP1KDM4E | |
| SCHEMBL2939401 | 0.83 | NQO1 (0.61) | ESR1ESR2CYP19A1PTPN1 | |
| SCHEMBL31675834 | 0.82 | ESR1 (0.82) | ESR1ESR2HSD17B3ERAP1KDM4E | |
| SCHEMBL5082203 | 0.82 | ESR1 (0.82) | ESR1ESR2HSD17B3ERAP1KDM4E | |
| SCHEMBL14315176 | 0.82 | HSD17B3 (0.74) | ESR1ESR2HSD17B3ERAP1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2007115181-A9 | COMPOUNDS EXHIBITING EFFLUX INHIBITOR ACTIVITY AND COMPOSITIONS AND USES THEREOF | EASTMAN CHEM CO (US) | 2008-04-03 | — | — | WO | disclosed |
| US-20070254859-A1 | Compounds exhibiting efflux inhibitor activity and composition and uses thereof | EASTMAN CHEMICAL COMPANY | 2007-11-01 | — | — | US | disclosed |
| WO-2007115181-A2 | COMPOUNDS EXHIBITING EFFLUX INHIBITOR ACTIVITY AND COMPOSITIONS AND USES THEREOF | EASTMAN CHEMICAL COMPANY (US) | 2007-10-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070254859-A1 | Compounds exhibiting efflux inhibitor activity and composition and uses thereof | ABCC4, NCOA4, NR4A3 | ESR1 258/4885ESR2 145/4885HSD17B3 339/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.